Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:634207rdf:typepubmed:Citationlld:pubmed
pubmed-article:634207lifeskim:mentionsumls-concept:C0341628lld:lifeskim
pubmed-article:634207lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:634207lifeskim:mentionsumls-concept:C0013819lld:lifeskim
pubmed-article:634207lifeskim:mentionsumls-concept:C0037982lld:lifeskim
pubmed-article:634207lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:634207pubmed:issue13lld:pubmed
pubmed-article:634207pubmed:dateCreated1978-5-24lld:pubmed
pubmed-article:634207pubmed:abstractTextEEG studies were done on patients with CNS disease who were treated with d-aldosterone and spirolactone. The baseline EEGs of these patients were found to be slightly abnormal. During infusion of the spirolactone derivative potassium canrenoate a transient deterioration of preexisting EEG disturbances was observed; in addition, bursts of increased muscle activity and transient relative bradycardia were seen. These findings indicate that potassium canrenoate or its lipophilic metabolite canrenone may affect the nervous system directly, possibly via a disturbance in the electrolyte balance. These results are compatible with recent findings in animal studies.lld:pubmed
pubmed-article:634207pubmed:languagegerlld:pubmed
pubmed-article:634207pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:634207pubmed:citationSubsetIMlld:pubmed
pubmed-article:634207pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:634207pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:634207pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:634207pubmed:statusMEDLINElld:pubmed
pubmed-article:634207pubmed:monthMarlld:pubmed
pubmed-article:634207pubmed:issn0025-8458lld:pubmed
pubmed-article:634207pubmed:authorpubmed-author:MertinJJlld:pubmed
pubmed-article:634207pubmed:authorpubmed-author:SimonOOlld:pubmed
pubmed-article:634207pubmed:authorpubmed-author:BrassBBlld:pubmed
pubmed-article:634207pubmed:issnTypePrintlld:pubmed
pubmed-article:634207pubmed:day31lld:pubmed
pubmed-article:634207pubmed:volume73lld:pubmed
pubmed-article:634207pubmed:ownerNLMlld:pubmed
pubmed-article:634207pubmed:authorsCompleteYlld:pubmed
pubmed-article:634207pubmed:pagination470-3lld:pubmed
pubmed-article:634207pubmed:dateRevised2007-8-13lld:pubmed
pubmed-article:634207pubmed:meshHeadingpubmed-meshheading:634207-H...lld:pubmed
pubmed-article:634207pubmed:meshHeadingpubmed-meshheading:634207-M...lld:pubmed
pubmed-article:634207pubmed:meshHeadingpubmed-meshheading:634207-E...lld:pubmed
pubmed-article:634207pubmed:meshHeadingpubmed-meshheading:634207-B...lld:pubmed
pubmed-article:634207pubmed:meshHeadingpubmed-meshheading:634207-F...lld:pubmed
pubmed-article:634207pubmed:meshHeadingpubmed-meshheading:634207-M...lld:pubmed
pubmed-article:634207pubmed:meshHeadingpubmed-meshheading:634207-E...lld:pubmed
pubmed-article:634207pubmed:meshHeadingpubmed-meshheading:634207-A...lld:pubmed
pubmed-article:634207pubmed:meshHeadingpubmed-meshheading:634207-S...lld:pubmed
pubmed-article:634207pubmed:meshHeadingpubmed-meshheading:634207-C...lld:pubmed
pubmed-article:634207pubmed:year1978lld:pubmed
pubmed-article:634207pubmed:articleTitle[EEG changes following spirolactone treatment (author's transl)].lld:pubmed
pubmed-article:634207pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:634207pubmed:publicationTypeEnglish Abstractlld:pubmed